FDA Clears First OTC CGM for Children: What Families Should Know

ByBrian “Weence” Bateman

On June 12, 2026, the FDA cleared the first over-the-counter continuous glucose monitor (CGM) for children age 2+ who do not use insulin. Here’s what the device can do, the key safety limits FDA emphasized, and practical steps for families to use glucose data responsibly.

On June 12, 2026, the FDA cleared the first over-the-counter (OTC) continuous glucose monitor (CGM) for children age 2 and older who do not use insulin. This can give families easier access to glucose readings and trends—but it does not replace clinician-guided diabetes care or glucose safety planning.

What changed on June 12, 2026

The FDA cleared for marketing Dexcom Inc.’s Stelo Glucose Biosensor System as an OTC CGM for eligible children. In everyday terms, the system uses a small wearable sensor paired with a smartphone app to show glucose information.

Who the clearance is for (and who it isn’t)

Intended for:

  • Children age 2+ who do not use insulin
  • Use with adult caregiver supervision for children

Key safety limits the FDA emphasized:

  • The device is not intended to alert for problematic hypoglycemia (dangerously low blood sugar).
  • It is not intended for people on dialysis.
  • Caregivers should consult a health care provider before making medication adjustments based on CGM output.

How it works in everyday terms

According to the FDA, Stelo provides:

  • Glucose readings and trends every 15 minutes
  • A sensor wear period of up to 15 days (FDA notes pediatric wear time may be shorter than in adults)

What CGM information can help with—and what it can’t

CGMs can support glucose awareness

CGMs measure glucose trends continuously and send data to a smartphone or other device. CDC notes that CGM results update over time and can help families see how routines like meals and activity relate to glucose patterns. CGM data can also be shared with the health care team when appropriate.

CGMs don’t always replace fingersticks

CDC emphasizes that many people mistakenly assume CGMs fully replace blood glucose checks. Because glucose measurements in the body’s fluids can differ from true blood glucose at certain times, CDC recommends confirming with fingerstick blood glucose checks as directed by a health care professional.

This OTC option isn’t built for dangerous low-blood-sugar alerts

A core reason for the FDA limitations is that this device is not designed to alert for problematic hypoglycemia. That means families should not assume they will get a warning for dangerous lows the way some diabetes devices with specific alarm features are intended to.

How to use it responsibly (practical checklist)

  • Confirm eligibility: Make sure the child is age 2+ and does not use insulin (and is not on dialysis).
  • Ask the child’s clinician for a plan: Get guidance on how to interpret trends and whether any fingerstick checks are needed.
  • Don’t change medications based on CGM alone: FDA advises discussing any medication changes with a health care provider.
  • Use adult supervision: FDA specifies that children should use the system under adult caregiver supervision.
  • Plan for lows using a clinician-approved action plan: Since the device is not intended to alert for problematic hypoglycemia, know what symptoms to watch for and what to do if they appear.

When to get professional help

Low blood sugar can become dangerous. MedlinePlus notes that for many people with diabetes, hypoglycemia is often defined as below 70 mg/dL (individual targets can vary). Symptoms can include shaking, sweating, nervousness/anxiety, irritability or confusion, dizziness, and hunger.

Get urgent help (or emergency care) if a child has symptoms of severe low blood sugar—such as confusion, inability to cooperate, or signs that they may be in danger—or if you’re worried that glucose is dangerously low.

Also contact a health care provider promptly if the child’s situation doesn’t match the intended use—for example, if insulin is involved.

Bottom line

The June 12, 2026 FDA clearance expands access to OTC CGM technology for eligible families. For children age 2+ who do not use insulin, Stelo can help build glucose awareness through trends every 15 minutes. Still, CGM data should be treated as additional information—and FDA’s safety limits (especially around problematic hypoglycemia alerts and clinician-guided medication decisions) should guide how families use it.

Key sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.

Related

Brian “Weence” Bateman is a health and medical writer who covers public health updates, healthcare policy, and medical developments affecting communities across the United States. He works closely with dentists and healthcare providers and focuses on making complex medical information clear, accurate, and useful for everyday readers.